S. Karger AG

SHERPA: Unknown

People

  1. O'Reilly
    O'Reilly
  2. Panageas
    Panageas
  3. Scheinberg
    Scheinberg
  4. Sun
    Sun

Groups

  1. Center for Hematologic Malignancies (8)
  2. GSK Faculty (8)
  3. Immunology Program Faculty (8)
  4. Sloan Kettering Institute Faculty (8)
  5. Department of Medicine (7)
  6. Hematologic Malignancies, Division of (7)
  7. Executive Committee, Center for Hematologic Malignancies (6)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  9. Hematologic Malignancies Research (2)
  10. Sloan Kettering Institute Postdocs (2)
Search Within
  1. "Immunology Program Faculty"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (1)
Groups
  1. Center for Hematologic Malignancies (8)
  2. GSK Faculty (8)
  3. Immunology Program Faculty (8)
  4. Sloan Kettering Institute Faculty (8)
  5. Department of Medicine (7)
  6. Hematologic Malignancies, Division of (7)

More Groups

People
  1. Marcel Van Den Brink (6)
  2. Barry Kappel (2)
  3. Jimmy Rotolo (2)
  4. Stephanie Muriglan (2)
  5. David Scheinberg (1)
  6. Joseph Sun (1)

More People

Years
  1. 2023 (1)
  2. 2019 (1)
  3. 2017 (1)
  4. 2016 (1)
  5. 2015 (1)
  6. 2010 (1)

More Years

Publications
  1. Oncology Research and Treatment (4)
  2. Acta Haematologica (2)
  3. Journal of Innate Immunity (1)
  4. Onkologie (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Tumor cell-intrinsic activity of the RNA receptor RIG-I promotes checkpoint inhibitor-mediated anticancer immunity
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Stritzke, F.; Bek, S.; Steiger, K.; Winter, C.; Rad, R.; van den Brink, M. R. M.; Ruland, J.; Bassermann, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Anti-CTLA-4 checkpoint inhibitormediated anticancer immunity relies on tumor-intrinsic RIG-I signaling
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Bek, S.; Schmickl, M.; Steiger, K.; Koenig, P. A.; Ruland, J.; van den Brink, M. R. M.; Peschel, C.; Haas, T.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Activation of the cytosolic RNA receptor RIG-I in tumor and immune cells triggers efficient anti-tumor immunity and synergizes with checkpoint blockade
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Kreppel, D.; Bscheider, M.; Bek, S.; Fischer, J.; Schmickl, M.; Ruland, J.; van den Brink, M.; Peschel, C.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Generation of natural killer cell memory during viral infection
    Journal Article

    O'sullivan, T. E.; Sun, J. C.
    Journal of Innate Immunity (2015)

    Fulltext@MSK | Save
  • How to improve immune reconstitution after SCT
    Meeting Abstract

    van den Brink, M. R. M.
    Onkologie (2010)

    Fulltext@MSK | Save
  • Interleukin-7 administration after allogeneic bone marrow transplantation enhances thymocyte, T and B cell reconstitution
    Meeting Abstract

    Alpdogan, O.; Muriglan, S. J.; Kappel, B. J.; Rotolo, J.; van den Brink, M. R. M.
    Acta Haematologica (2000)

    Fulltext@MSK | Save
  • The role of the Fas ligand and perforin cytotoxic pathways in graft-versus-host-disease, graft-versus-leukemia and donor leukocyte infusion
    Meeting Abstract

    Kappel, B. J.; Muriglan, S. J.; Rotolo, J.; Horndasch, K. J.; Teshima, T.; Ferrara, J. L.; Burakoff, S. J.; van den Brink, M. R. M.
    Acta Haematologica (2000)

    Fulltext@MSK | Save